Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
conatumumab
- Development stage
- Phase 2
- Lead developer
- Amgen
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous
01
Overview
Conatumumab is a fully human monoclonal antibody developed for the treatment of cancer. It acts as an agonist of tumor necrosis factor-related apoptosis-inducing ligand receptor 2 (TRAIL-R2, also known as death receptor 5 or DR5, TNFRSF10B). By binding to and activating TRAIL-R2/DR5 on tumor cells, conatumumab mimics the activity of native TRAIL, triggering caspase cascades that induce apoptosis in tumor cells. This mechanism selectively targets a variety of solid tumors and hematopoietic cancers with minimal toxicity to normal cells. Conatumumab was initially developed by Amgen and later licensed to Takeda for development in Japan; however, all clinical development has been discontinued.
- Other names
- conatumumabanti-TRAIL receptor 2 monoclonal antibody
02
Targets
TNFRSF10B (DR5)
Beyond the preview
Go deeper on conatumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on conatumumab.